n Scientific remains the overall drug-eluting stent market leader in the United States, with a 49 percent share of the market in December. The Company released three major DES products in the United States in 2008 with the PROMUS(R) Everolimus-Eluting Coronary Stent, the TAXUS Express Atom Stent and the TAXUS Liberte Stent. The Company expects to launch its third-generation drug-eluting stents -- the TAXUS Element(TM) Paclitaxel-Eluting Coronary Stent and the PROMUS Element Everolimus-Eluting Coronary Stent -- in Europe later this year.
The TAXUS Liberte Atom, TAXUS Liberte Long, TAXUS Element and PROMUS Element stents are investigational devices and are restricted under U.S. law to investigational use only.
The PROMUS(R) Stent is a private-labeled XIENCE(TM) V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. XIENCE(TM) V is a trademark of the Abbott Laboratories group of companies.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding regulatory approvals,
Page: 1 2 3 4 5 Related medicine technology :1
|SOURCE Boston Scientific Corporation|
Copyright©2009 PR Newswire.
All rights reserved
. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent2
. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent3
. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 20084
. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent5
. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)6
. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute7
. Boston Scientific Announces Schedule for European Society of Cardiology Congress 20088
. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services9
. Headache Specialists Convene in Boston For 50th Annual American Headache Society Meeting10
. Leading Immunologists Convene in Boston11
. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City